Confirmed Preliminary Control Announced Transaction verified BiotechLife SciencesoncologyTherapeutics

Myricx Bio acquired by Novartis

Novartis agreed to acquire Myricx Bio, a UK therapeutics brand, on Jul 6, 2026.

Preliminary: The announcement date, transaction value, value basis and value notes are not yet independently verified.

Transaction summary

Target
Myricx Bio
Acquirer
Novartis
Seller
-
Announced
2026-07-06(unverified)
Geography
United Kingdom
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-07-13
Latest update
2026-10-29

Value and multiples

100% enterprise value

USD 1.5B

Unverified

100% enterprise value | USD

Basis: Estimated

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

EV / revenue

-

Period not stated

Basis: FundComb estimate

EV / EBITDA

-

EBITDA basis not stated

Basis: FundComb estimate

Amounts paid and other reported values

Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.

Consideration: USD 1.5B

The headline says Novartis agreed to acquire Myricx Bio for up to US$1.5bn.

Basis

  • Estimated consideration: USD 1.5bn.

Source summary

UK: Novartis agrees to acquire Myricx Bio for up to US$1.5bn - Investors in Healthcare

Confirmed

Investors in Healthcare headline reports that Novartis agreed to acquire UK-based Myricx Bio for up to US$1.5bn, published July 6, 2026.

Open source

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis - Business Wire

Confirmed

Business Wire announcement reports that Myricx Bio agreed to be acquired by Novartis; Sofinnova Partners is referenced in the announcement.

Open source

Continue your research

Explore more comps →